The AGITG ICECREAM STUDY: The Irinotecan Cetuximab Evaluation and Cetuximab Response Evaluation Amongst Patients with a G13D Mutation- analysis of outcomes in patients with “Quad WT”. J Clin Oncol 35 (15) 3572.

Eva Segelov, Jeremy Shapiro, Subotheni Thavaneswaran, Paul Waring, Jayesh Desai, Kirsty Mann, Maria Elena Elez, Lorraine A Chantrill, Nick Pavlakis, Louise Nott, C Underhill, Mustafa Khasraw, Harpreet Wasan, Fortunato Ciardiello, Michael J Jefford, Warren Joubert, Andrew Mark Meurisse Haydon, Christos Karapetis, Tim J. Price, Kate Wilson

Research output: Contribution to conferencePoster

Original languageEnglish
Pages3572
Number of pages1
DOIs
Publication statusPublished - 2017

Cite this

Segelov, E., Shapiro, J., Thavaneswaran, S., Waring, P., Desai, J., Mann, K., Elez, M. E., Chantrill, L. A., Pavlakis, N., Nott, L., Underhill, C., Khasraw, M., Wasan, H., Ciardiello, F., Jefford, M. J., Joubert, W., Haydon, A. M. M., Karapetis, C., Price, T. J., & Wilson, K. (2017). The AGITG ICECREAM STUDY: The Irinotecan Cetuximab Evaluation and Cetuximab Response Evaluation Amongst Patients with a G13D Mutation- analysis of outcomes in patients with “Quad WT”. J Clin Oncol 35 (15) 3572.. 3572 . https://doi.org/10.1200/JCO.2017.35.15_suppl.